(123-B9)2

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Name(123-B9)2
Drug Alias NameEphA2 receptor tyrosine kinase inhibitor (University of California Riverside/Cedars-Sinai Medical Center)(123-B9)2
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEphrin type-A receptor 2 modulators
TargetsEphrin type-A receptor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of California, Riverside
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCedars-Sinai Medical CenterUniversity of California, Riverside
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A